Skip to content

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine

PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine in Adults, Including Randomized Comparison of Concurrent or Delayed Seasonal Influenza Vaccination

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01000584
Enrollment
309
Registered
2009-10-23
Start date
2009-11-30
Completion date
2010-02-28
Last updated
2015-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H1N1 2009 Influenza, Influenza

Keywords

vaccine, H1N1, influenza, H1N1 influenza vaccine, influenza vaccine, seasonal Influenza

Brief summary

The purpose of this study is to assess the safety and effectiveness (immune response) to a licensed H1N12009 influenza vaccine in adults when given at the same time or prior to the seasonal influenza vaccine. The study will enroll 300 adults (ages 20-59 years). Participants will be randomized into 2 groups. One group will receive one dose of a licensed H1N1 vaccine and one dose of the seasonal influenza vaccine at the same time; the second group will receive the seasonal influenza vaccine 3 weeks after receiving the licensed H1N12009 influenza vaccine. Study procedures include: medical history, blood samples and completing a memory aid. Participants will be involved in study related procedures for approximately 3-6 weeks depending upon the group assignment.

Detailed description

The objectives of this study are two-fold: 1. To evaluate the safety and immunogenicity of H1N12009 influenza vaccine in a convenience sample of adults, soon after the pandemic vaccine becomes available so as to inform the subsequent use of vaccine in public programs. 2. To evaluate the compatibility of co-administered H1N12009 pandemic vaccine and seasonal TIV vaccine in the same group of subjects, as the option of co-administration would be useful for public programs.

Interventions

BIOLOGICALArepanrix, Vaxigrip 2009/2010

Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
David Scheifele
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 59 Years
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent * Adults 20-59 years of age

Exclusion criteria

* Allergies to eggs, thimerosal, gentamicin sulphate, neomycin * Life-threatening reaction to previous Flu vaccine * Bleeding disorder * Pregnancy * Receipt of blood or blood products in past 3 months * Chronic illness * Compromised immune system * Previous lab-confirmed H1N12009 infection * Receipt of H1N12009 vaccine * Receipt of Seasonal Influenza vaccine since March 2009

Design outcomes

Primary

MeasureTime frame
Occurrence of adverse events (AEs) for days 0-6 after each vaccinationDay 7 and Day 21 post vaccination
Occurrence of serious adverse events (SAEs) and other significant health events up to 21 days after each vaccinationDay 7 and Day 21 post vaccination

Secondary

MeasureTime frame
Immunogenicity: Comparison of baseline and post-immunization antibody titresDay 21 post vaccination

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026